12:00 AM
 | 
Jan 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Naproxcinod: Phase III data

A pre-specified pooled analysis of 2,734 OA patients from 3 Phase III trials (Studies 301 and 302 to treat OA of the knee and Study 303 to treat OA of the hip) showed that both 375 and 750 mg...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >